光啟技術(002625.SZ):子公司簽訂先進多功能超材料機載產品獨家研製任務協議
格隆匯10月12日丨光啟技術(002625.SZ)宣佈,公司於近日收到下屬子公司深圳光啟尖端技術有限責任公司(下稱“光啟”)的通知,光啟作為一級配套製造商於2020年10月11日與瀋陽某重要客户簽訂基於超材料的先進多功能機載產品獨家研製任務協議等相關協議。
其中,部分產品的首筆研製經費撥付協議6500萬元。協議所含產品總重量佔整機機體結構重量近10%,該系列超材料航空產品價值佔整機價值比例不低於其重量佔比,是超材料技術大規模全面應用的里程碑。
公司表示,上述事項會在該系列超材料先進多功能航空機載產品的研製期間持續給公司帶來研製訂單及收入,研製完成後將持續給公司帶來批產訂單及收入,對公司2020年以及未來財務狀況和經營成果產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.